You are here

Generic Loestrin Tablets Approved

WOODCLIFF LAKE, N.J., Sept. 18 /PRNewswire-FirstCall/ -- Barr Laboratories, Inc. (NYSE:BRL) today announced that the U.S. Food and Drug Administration (FDA) has approved its applications to manufacture and market generic versions of Galen's Loestrin(R) Fe 1/20 and 1.5/30 Tablets, USP, oral contraceptives. The Company plans to market the products as generics under the trademark names Junel(TM) Fe 1/20 and Junel(TM) Fe 1.5/30. The Company will launch both its Junel Fe products and its Junel(TM) 21 1/20 and Junel(TM) 21 1.5/30 products, which were approved in late May 2003, immediately.

"With the launch of our Junel oral contraceptive products we continue to solidify Barr's position in the $2.9 billion U.S. oral contraceptive marketplace," said Bruce L. Downey, Barr's Chairman and CEO. "These most recent launches increase our currently marketed generic oral contraceptive product portfolio to 15."

Junel Fe 1/20 is a regimen consisting of 21 oral contraceptive tablets that contain 1 mg of norethindrone acetate and 0.02 mg of ethinyl estradiol, and 7 ferrous fumarate tablets. Junel Fe 1.5/30 is a regimen consisting of 21 oral contraceptive tablets that contain 1.5 mg of norethindrone acetate and 0.03 mg of ethinyl estradiol, and 7 ferrous fumarate tablets. Both products are indicated for the prevention of pregnancy in women who elect to use the product as a method of contraception and are supplied in a 28-day regimen.

Junel Fe 1/20 and Junel Fe 1.5/30 will compete in a market that had combined annual sales of approximately $194 million for the twelve months ending July 2003. Junel 21 1/20 and Junel 21 1.5/30 will compete in a market that had combined annual sales of approximately $19.2 million for the twelve months ending July 2003.

Source: Barr Laboratories, Inc.

Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Acasti reports disappointing results for a second Omega-3-based drug
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks